Growth Metrics

Gilead Sciences (GILD) EPS (Basic) (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -7.39%
Dec 31, 2025 -28.46%
Sep 30, 2025 56.69%
Jun 30, 2025 48.11%
Mar 31, 2025 -25.35%
Dec 31, 2024 42.00%
Sep 30, 2024 -22.48%
Jun 30, 2024 138.62%
Mar 31, 2024 -390.43%
Dec 31, 2023 -34.29%
Sep 30, 2023 108.33%
Jun 30, 2023 3.70%
Mar 31, 2023 -38.17%
Dec 31, 2022 -8.39%
Sep 30, 2022 57.14%
Jun 30, 2022 4,450.00%
Mar 31, 2022 -93.55%
Dec 31, 2021 -84.95%
Sep 30, 2021 70.25%
Jun 30, 2021 -12.32%
Mar 31, 2021 11.29%
Dec 31, 2020 327.59%
Sep 30, 2020 110.90%
Jun 30, 2020 -316.26%
Mar 31, 2020 -42.25%
Dec 31, 2019 331.52%
Sep 30, 2019 -162.16%
Jun 30, 2019 -4.52%
Mar 31, 2019 615.98%
Dec 31, 2018 -86.64%
Sep 30, 2018 15.71%
Jun 30, 2018 18.64%
Mar 31, 2018 139.86%
Dec 31, 2017 -242.31%
Sep 30, 2017 -11.49%
Jun 30, 2017 13.53%
Mar 31, 2017 -12.29%
Dec 31, 2016 -6.35%
Sep 30, 2016 -3.82%
Jun 30, 2016 1.55%
Mar 31, 2016 -20.86%
Dec 31, 2015 3.82%
Sep 30, 2015 2.95%
Jun 30, 2015 4.81%
Mar 31, 2015 25.43%
Dec 31, 2014 28.89%
Sep 30, 2014 -24.69%
Jun 30, 2014 64.83%
Mar 31, 2014 178.85%
Dec 31, 2013 1.96%
Sep 30, 2013 0.00%
Jun 30, 2013 8.51%
Mar 31, 2013 -6.00%
Dec 31, 2012 11.11%
Sep 30, 2012 -4.26%
Jun 30, 2012 62.07%
Mar 31, 2012 -34.09%
Dec 31, 2011 -8.33%
Sep 30, 2011 0.00%
Jun 30, 2011 17.07%
Mar 31, 2011 -47.44%
Dec 31, 2010 -8.24%
Sep 30, 2010 4.94%
Jun 30, 2010 -14.74%
Mar 31, 2010 6.74%
Dec 31, 2009 18.67%
Sep 30, 2009 19.05%
Jun 30, 2009 -3.08%